Zorgstandaard Neurofibromatose Type 1

100 / 113

100
[187] M. G. Kumar, R. J. Emnett, S. J. Bayliss, and D. H. Gutmann, “Glomus tumors in individuals with
neurofibromatosis type 1,” J. Am. Acad. Dermatol., vol. 71, no. 1, pp. 44–48, Jul. 2014.
[188] B. Harrison, A. M. Moore, R. Calfee, and D. M. Sammer, “The association between glomus tumors
and neurofibromatosis,” J. Hand Surg., vol. 38, no. 8, pp. 1571–1574, Aug. 2013.
[189] M. Fenot, J.-F. Stalder, and S. Barbarot, “Juvenile xanthogranulomas are highly prevalent but
transient in young children with neurofibromatosis type 1,” J. Am. Acad. Dermatol., vol. 71, no. 2, pp.
389–390, Aug. 2014.
[190] F. Ferrari, A. Masurel, L. Olivier-Faivre, and P. Vabres, “Juvenile xanthogranuloma and nevus
anemicus in the diagnosis of neurofibromatosis type 1,” JAMA Dermatol., vol. 150, no. 1, pp. 42–46, Jan.
2014.
[191] G. Tadini, M. Brena, L. Pezzani, C. Gelmetti, F. Santagada, and M. P. Boldrini, “Anemic nevus in
neurofibromatosis type 1,” Dermatol. Basel Switz., vol. 226, no. 2, pp. 115–118, 2013.
[192] N. Mimoun, N. Razzouq, P. Wolkenstein, J. C. Moreno, J. P. Marty, L. Lantieri, A. Astier, and M. Paul,
“Evaluation of skin viscoelasticity in type 1 neurofibromatosis patients,” Skin Pharmacol. Physiol., vol. 19,
no. 1, pp. 22–27, 2006.
[193] J. R. Sty, R. J. Starshak, and G. A. Woods, “Neurofibromatosis: lymphoscintigraphic observations,”
Clin. Nucl. Med., vol. 6, no. 6, pp. 264–265, Jun. 1981.
[194] J. Finsterer, C. Stollberger, E. Stubenberger, and S. Tschakoschian, “Lymphangiopathy in
neurofibromatosis 1 manifesting with chylothorax, pericardial effusion, and leg edema,” Int. J. Gen.
Med., vol. 6, pp. 743–746, 2013.
[195] National Cancer Institute, “Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and
Race/Ethnicity: Males, 18 SEER Areas, 2009-2011 (Table 1.16) and Females, 18 SEER Areas, 2009-2011
(Table 1.17).” [Online]. Available:
[Accessed: 24-
Sep-2014].
[196] H. Brems, E. Beert, T. de Ravel, and E. Legius, “Mechanisms in the pathogenesis of malignant
tumours in neurofibromatosis type 1,” Lancet Oncol., vol. 10, no. 5, pp. 508–515, May 2009.
[197] S. Laycock-van Spyk, N. Thomas, D. N. Cooper, and M. Upadhyaya, “Neurofibromatosis type 1-
associated tumours: their somatic mutational spectrum and pathogenesis,” Hum Genomics, vol. 5, no. 6,
pp. 623–690, 2011.
[198] IKNL, “Herstel na kanker.” 2011.
[199] R. DeLellis, P. Heitz, and C. Eng, Eds., “Neurofibromatosis type 1,” in Pathology and Genetics of
Tumours of Endocrine Organs, 1 edition., Lyon: World Health Organization, 2004, p. pp 243–248.
[200] M. Upadhyaya, “Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors,”
Front Biosci, vol. 16, pp. 937–51.
[201] S. L. Ardern-Holmes and K. N. North, “Therapeutics for Childhood Neurofibromatosis Type 1 and
Type 2,” Curr Treat Options Neurol .
[202] S. Cambiaghi, L. Restano, and R. Caputo, “Juvenile xanthogranuloma associated with
neurofibromatosis 1: 14 patients without evidence of hematologic malignancies,” Pediatr. Dermatol.,
vol. 21, no. 2, pp. 97–101, Apr. 2004.
[203] J. Lachenaud, M. Strullu, A. Baruchel, and H. Cavé, “[Juvenile myelomonocytic leukemias],” Bull.
Cancer (Paris), vol. 101, no. 3, pp. 302–313, Mar. 2014.
[204] S. A. Madanikia, A. Bergner, X. Ye, and J. O. Blakeley, “Increased risk of breast cancer in women with
NF1,” Am. J. Med. Genet. A., vol. 158A, no. 12, pp. 3056–3060, Dec. 2012.
[205] K. C. Lakshmaiah, A. N. Kumar, S. Purohit, B. K. Viveka, K. R. Rajan, M. A. L. Zameer, P. Namitha, M. L.
Saini, H. A. Azim, and K. S. Saini, “Neurofibromatosis type I with breast cancer: not only for women!,”
Hered. Cancer Clin. Pract., vol. 12, no. 1, p. 5, 2014.
[206] Oncoline, “Landelijke richtlijn mammacarcinoom.” 13-Feb-2012.